<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="36674">
  <!-- This xml conforms to an XML Schema at:
    http://clinicaltrials.gov/ct2/html/images/info/public.xsd
 and an XML DTD at:
    http://clinicaltrials.gov/ct2/html/images/info/public.dtd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on June 04, 2014</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>http://clinicaltrials.gov/show/NCT01709721</url>
  </required_header>
  <id_info>
    <org_study_id>CNS-HYD201US</org_study_id>
    <nct_id>NCT01709721</nct_id>
  </id_info>
  <brief_title>Safety and Efficacy Study of Hydromorphone HCl by Intrathecal Administration Using a Programmable Implantable Pump</brief_title>
  <official_title>A Controlled, Two-Arm, Parallel Group, Randomized Withdrawal Study to Assess the Safety and Efficacy of Hydromorphone Hydrochloride Delivered by Intrathecal Administration Using a Programmable Implantable Pump</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>CNS Therapeutics</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Pacific-Link Consulting LLC</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>CNS Therapeutics</source>
  <oversight_info>
    <authority>United States: Food and Drug Administration</authority>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to determine the safety and efficacy of hydromorphone
      hydrochloride by intrathecal administration using a programmable implantable pump.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      A Controlled, Two-Arm, Parallel Group, Randomized Withdrawal Study to Assess the Safety and
      Efficacy of Hydromorphone Hydrochloride Delivered by Intrathecal Administration Using a
      Programmable Implantable Pump
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date>February 2013</start_date>
  <completion_date type="Anticipated">December 2015</completion_date>
  <primary_completion_date type="Anticipated">December 2014</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <study_design>Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Supportive Care</study_design>
  <primary_outcome>
    <measure>Superiority of intrathecal hydromorphone hydrochloride as compared to a control arm.</measure>
    <time_frame>4 weeks</time_frame>
    <safety_issue>No</safety_issue>
    <description>The primary efficacy endpoint is the proportion of subjects who are treatment failures during the double-blind randomized withdrawal period.  A subject who experiences an increase of 20 mm or more points on a 100 mm VASPI, based on a 3-day average, or who experiences intolerable pain that requires intervention, will be considered a treatment failure</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Functionality based on a Brief Pain Inventory</measure>
    <time_frame>18 weeks</time_frame>
    <safety_issue>No</safety_issue>
    <description>Patients ability to function and perform tasks without significant pain based on the BPI scale.</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">250</enrollment>
  <condition>Management of Chronic Pain</condition>
  <arm_group>
    <arm_group_label>Active</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Subjects on hydromorphone hydrochloride for the duration of therapy.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Titrated off therapy</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Subjects on control</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Hydromorphone Hydrochloride</intervention_name>
    <description>Subjects who meet criteria for randomization, will be randomized in a 1:1 ratio to either the active arm or control arm.</description>
    <arm_group_label>Active</arm_group_label>
    <other_name>Hydromorphone</other_name>
    <other_name>Opioid</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Hydromorphone Hydrochloride</intervention_name>
    <description>Active Control Based on Dose Reduction</description>
    <arm_group_label>Titrated off therapy</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          1. Subject must be at least 18 years of age and no more than 75 years old. of the
             following criteria to be included:

          2. Clinically diagnosed with chronic pain for at least a 6-month period.

          3. Subject is presently on intrathecal pain medication and has a SynchroMed II
             Implantable pump or meets clinical criteria for implantation of a SynchroMed II
             Implantable pump.

          4. Subject agrees to sign a Pain Treatment Agreement (Narcotic Contract) limiting
             narcotic prescriptions to the study physician.

          5. Subject must be cognitively intact and, in the opinion of the investigator, capable
             of participation in the trial.

          6. Female subjects of child-bearing potential must agree to use a medically acceptable
             and effective double-barrier method of birth control.

          7. Patients with existing SynchroMed II Implantable pumps and are reasonably expected to
             benefit from intrathecal opioid therapy.

          8. Subjects who are capable of receiving an MRI if required by the study protocol.

          9. Provides written Ethics Committee approved informed consent.

         10. Willing to comply with all study procedures and requirements.

        Exclusion Criteria:

          1. Women who are pregnant or are breast-feeding of the following criteria will be
             excluded:

          2. Subjects who have participated in an investigational drug or device trial within 4
             weeks prior to enrollment.

          3. Subject has any known or suspected allergy to hydromorphone or to the materials of
             the infusion pump or intrathecal catheter.

          4. Subjects who show signs of active systemic infection.

          5. Subjects with a metastatic cancer to the spinal canal or a known central nervous
             system contraindication to intrathecal therapy.

          6. Subject has a condition requiring diathermy procedures.

          7. Subject has a life expectancy of less than 12 months.

          8. Subject cannot independently comprehend and participate in the required assessments,
             including responding to the VASPI, SF-MPQ, COWS, BPI and PGIC measurement tools.

          9. Subject is not considered to be medically or psychologically appropriate for pump
             implantation.

         10. Subjects who are unable or unwilling to return to all of the required follow-up
             visits.

             Subjects with active implanted devices such as pacemakers, defibrillators, and
             cochlear implants or other medical device use, if in the opinion of the investigator
             the device would interfere with the function of the implantable intrathecal pump.

         11. As a result of medical review and physical examination, the Investigator considers
             the subject unfit for the study.

         12. Pain located above the shoulders in the head or neck region (e.g. trigeminal
             neuralgia), central pain syndromes or any other condition in which it is judged to be
             unlikely that the patient would benefit from intrathecal administration of the drug
             product.

         13. Subjects who have previously been unresponsive to intrathecal hydromorphone therapy.
      </textblock>
    </criteria>
    <gender>Both</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>75 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Richard L Rauck, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>The Center for Clinical Research</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Richard E Lowenthal, MSc</last_name>
    <phone>858-335-1300</phone>
    <email>richard@pacificlinkconsulting.com</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Sarina Tanimoto, MD</last_name>
    <phone>858-227-3008</phone>
    <email>sarina@pacificlinkconsulting.com</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Alabama Pain Center</name>
      <address>
        <city>Huntsville</city>
        <state>Alabama</state>
        <zip>35801</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Leah Pinkerton, BSN, RN</last_name>
      <phone>256-882-2003</phone>
      <phone_ext>1300</phone_ext>
      <email>lpinkerton@alabamapaincenter.com</email>
    </contact>
    <investigator>
      <last_name>K. Dean Willis, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Center for Pain and Supportive Care</name>
      <address>
        <city>Phoenix</city>
        <state>Arizona</state>
        <zip>85028</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Lisa Stearns, MD</last_name>
      <phone>480-889-0180</phone>
      <email>ljstearns@yahoo.com</email>
    </contact>
    <contact_backup>
      <last_name>Krisstin Hammond</last_name>
      <phone>480.516.0233</phone>
    </contact_backup>
    <investigator>
      <last_name>Lisa Stearns, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Neurovations</name>
      <address>
        <city>Napa</city>
        <state>California</state>
        <zip>94558</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Eric Grigsby, MD, MBA</last_name>
      <phone>707-252-9606</phone>
      <email>eg@neurovations.com</email>
    </contact>
    <contact_backup>
      <last_name>Whitney Michiels</last_name>
      <phone>707-252-9606</phone>
      <email>whitney@neurovations.com</email>
    </contact_backup>
    <investigator>
      <last_name>Eric Grigsby, MD, MBA</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>National Pain Research Institute, LLC</name>
      <address>
        <city>Winter Park</city>
        <state>Florida</state>
        <zip>32789</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Cherian K Sajan, MD</last_name>
      <phone>407-622-5766</phone>
      <email>csajan@natpain.com</email>
    </contact>
    <contact_backup>
      <last_name>Joan Cutillo</last_name>
      <phone>407-622-5766</phone>
      <email>jcutillo@natpain.com</email>
    </contact_backup>
    <investigator>
      <last_name>Cherian K Sajan, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Advocate Healthcare</name>
      <address>
        <city>Normal</city>
        <state>Illinois</state>
        <zip>61761</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Ramsin Benyamin, MD</last_name>
    </contact>
    <investigator>
      <last_name>Ramsin Benyamin, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Pain Care Associates</name>
      <address>
        <city>Bloomfield Hills</city>
        <state>Michigan</state>
        <zip>48302</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Todd Lininger, MD</last_name>
      <phone>248-751-7246</phone>
      <email>telininger@gmail.com</email>
    </contact>
    <contact_backup>
      <last_name>Kelli Bocan</last_name>
      <phone>248-751-7246</phone>
      <phone_ext>421</phone_ext>
      <email>kbocan@npcmi.com</email>
    </contact_backup>
    <investigator>
      <last_name>Todd Lininger, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>William Beaumont Hospital</name>
      <address>
        <city>Royal Oak</city>
        <state>Michigan</state>
        <zip>48073</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Michael Sikorsky, DO</last_name>
      <email>sikorskymsu@yahoo.com</email>
    </contact>
    <contact_backup>
      <last_name>Cynthia Turzewski, RN</last_name>
      <phone>248.898.1907</phone>
      <email>Cynthia.Turzewski@beaumont.edu</email>
    </contact_backup>
    <investigator>
      <last_name>Michael Sikorsky, DO</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>The Center for Clinical Research</name>
      <address>
        <city>Winston-Salem</city>
        <state>North Carolina</state>
        <zip>27103</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Richard Rauck, MD, FACP</last_name>
    </contact>
    <investigator>
      <last_name>Richard L Rauck, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Nagy Mekhail</name>
      <address>
        <city>Cleveland</city>
        <state>Ohio</state>
        <zip>44195</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Hani Yousef</last_name>
      <phone>216-636-1484</phone>
      <email>yousefh@ccf.org</email>
    </contact>
    <investigator>
      <last_name>Nagy Mekhail, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Moss Rehab</name>
      <address>
        <city>Elkins Park</city>
        <state>Pennsylvania</state>
        <zip>19027</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Michael Saulino, MD, PhD</last_name>
      <phone>215-663-6607</phone>
      <email>docsaulino@msn.com</email>
    </contact>
    <contact_backup>
      <last_name>Marianne Pedicone, RN, BA, CRRN</last_name>
      <phone>215-663-6112</phone>
      <email>pedicone007@comcast.net</email>
    </contact_backup>
    <investigator>
      <last_name>Michael Saulino, MD, PhD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Vanderbilt University Medical Center</name>
      <address>
        <city>Nashville</city>
        <state>Tennessee</state>
        <zip>37232</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Marc Huntoon, MD</last_name>
      <phone>615-322-6033</phone>
      <email>marc.huntoon@vanderbilt.edu</email>
    </contact>
    <contact_backup>
      <last_name>Donna Nelson, RN</last_name>
      <phone>615-343-9769</phone>
      <email>donna.nelson@vanderbilt.edu</email>
    </contact_backup>
    <investigator>
      <last_name>Marc Huntoon, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Houston Pain Centers</name>
      <address>
        <city>Houston</city>
        <state>Texas</state>
        <zip>77030</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Allen Burton, MD</last_name>
      <phone>713-737-7246</phone>
      <email>awburtonmd@gmail.com</email>
    </contact>
    <contact_backup>
      <last_name>Erica N Butler</last_name>
      <phone>713-973-7246</phone>
      <email>ebutler@houstonpainassociates.com</email>
    </contact_backup>
    <investigator>
      <last_name>Allen Burton, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>The Center for Pain Relief Tri-State</name>
      <address>
        <city>Huntington</city>
        <state>West Virginia</state>
        <zip>25702</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>David Caraway, MD, PhD</last_name>
      <phone>304-526-8384</phone>
      <email>carawaymd@aol.com</email>
    </contact>
    <contact_backup>
      <last_name>Kathy Clagg, RN</last_name>
      <phone>304 526-8384</phone>
      <email>kclagg@st-marys.org</email>
    </contact_backup>
    <investigator>
      <last_name>David Caraway, MD, PhD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>August 2013</verification_date>
  <lastchanged_date>August 14, 2013</lastchanged_date>
  <firstreceived_date>August 24, 2012</firstreceived_date>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Hydromorphone</keyword>
  <keyword>Hydromorphone Hydrochloride</keyword>
  <keyword>Pain Management</keyword>
  <keyword>Non-narcotic analgesics</keyword>
  <is_fda_regulated>Yes</is_fda_regulated>
  <is_section_801>Yes</is_section_801>
  <has_expanded_access>No</has_expanded_access>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Hydromorphone</mesh_term>
    <mesh_term>Analgesics, Non-Narcotic</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                -->
</clinical_study>
